Researchsemaglutidetirzepatidecardiovascular outcomeshfpef

Review maps GLP-1 and tirzepatide cardiovascular outcome evidence for cardiologists

Authors say SURPASS-CVOT showed tirzepatide noninferior to dulaglutide on major adverse cardiovascular events but did not demonstrate superiority.

By Priya Raman · Science Reporter

Sep 15 20:00 ETSource: Frontiers in cardiovascular medicine

The wire

01A Frontiers in Cardiovascular Medicine review integrates SELECT, SOUL, SURPASS-CVOT and FLOW, and proposes a phenotype-directed algorithm covering atherosclerotic disease, obesity, type 2 diabetes, chronic kidney disease, HFpEF and SGLT2 inhibitor use.
02The authors argue prescribing should follow indication-specific outcome evidence rather than weight-loss magnitude or indirect cross-trial comparisons, a caution for clinicians choosing between agents.
03Endothelial, coronary microvascular and direct myocardial mechanisms remain less clinically validated; this is a narrative review, not new trial data.

From the source

Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology
Frontiers in cardiovascular medicine · 2026 · Li M et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42819943/